TransMedics: Despite Earnings Miss, Growth Story Remains Intact (NASDAQ:TMDX)

Executive Summary

TransMedics (TMDX) is still rated a Strong Buy after a 50% drop and Q1 miss—see growth drivers, Europe rollout, guidance, and margin targets. Read the full analysis here.